
Aytu BioScience Long-Term Debt | AYTU
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Aytu BioScience
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.1 M | 10.9 M | 10.9 M | 14.7 M | 15 M | 180 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 15 M | 180 K | 10.1 M |
Quarterly Long-Term Debt Aytu BioScience
| 2027-Q1 | 2026-Q4 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 785 K | 853 K | 9.55 M | 10 M | 10.4 M | 10 M | 10.4 M | 1.11 M | 9.54 M | 9.98 M | 10.4 M | 15 M | - | 15 M | 1.15 M | 1.47 M | 1.77 M | 2.09 M | 2.41 M | 15 M | 2.76 M | 2.62 M | 2.87 M | 211 K | 237 K | 725 K | 804 K | 292 K | 314 K | 23.4 M | 5.13 M | 5.04 M | 5.13 M | 5.04 M | - | 5.04 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 23.4 M | 211 K | 5.78 M |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Concert Pharmaceuticals
CNCE
|
13.9 M | - | - | $ 401 M | ||
|
Histogen
HSTO
|
5 K | - | 31.6 % | $ 2.12 M | ||
|
Checkpoint Therapeutics
CKPT
|
2.47 M | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
437 M | - | -7.23 % | $ 13 M | ||
|
Taro Pharmaceutical Industries Ltd.
TARO
|
4.98 M | - | - | $ 1.62 B | ||
|
Omeros Corporation
OMER
|
87.9 M | $ 13.23 | -5.71 % | $ 840 M | ||
|
BioLineRx Ltd.
BLRX
|
977 K | $ 0.94 | -10.44 % | $ 2.32 B | ||
|
PhaseBio Pharmaceuticals
PHAS
|
1.36 M | - | 7.4 % | $ 6.29 M | ||
|
Forma Therapeutics Holdings
FMTX
|
27.6 M | - | - | $ 958 M | ||
|
Blueprint Medicines Corporation
BPMC
|
68.8 M | - | - | $ 8.14 B | ||
|
Horizon Therapeutics Public Limited Company
HZNP
|
2.55 B | - | - | $ 26.6 B | ||
|
Provention Bio
PRVB
|
23.5 M | - | - | $ 2.37 B | ||
|
Reata Pharmaceuticals
RETA
|
117 M | - | - | $ 6.29 B | ||
|
PainReform Ltd.
PRFX
|
30 K | $ 0.47 | -24.53 % | $ 305 K | ||
|
iTeos Therapeutics
ITOS
|
3.76 M | - | - | $ 411 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
15 K | $ 1.44 | -2.03 % | $ 2.37 M | ||
|
PolarityTE
PTE
|
41 K | - | -0.82 % | $ 1.78 M | ||
|
Kronos Bio
KRON
|
21.5 M | - | 1.49 % | $ 50.8 M | ||
|
Cullinan Management
CGEM
|
1.9 M | $ 8.9 | -1.93 % | $ 536 M | ||
|
CRISPR Therapeutics AG
CRSP
|
188 M | $ 39.15 | 0.57 % | $ 3.52 B | ||
|
Advaxis
ADXS
|
8.14 M | - | -9.65 % | $ 45.9 M | ||
|
Stoke Therapeutics
STOK
|
1.14 M | $ 26.77 | -0.59 % | $ 1.59 B | ||
|
Trevena
TRVN
|
30.8 M | - | -46.58 % | $ 31.8 M | ||
|
Calithera Biosciences
CALA
|
136 K | - | -10.95 % | $ 876 K | ||
|
Molecular Templates
MTEM
|
9.74 M | - | -23.43 % | $ 495 K | ||
|
Oncorus
ONCR
|
20 M | - | -8.54 % | $ 3.19 M | ||
|
BioXcel Therapeutics
BTAI
|
84.7 M | $ 0.07 | 9.81 % | $ 855 K | ||
|
Novan
NOVN
|
3.74 M | - | -24.84 % | $ 2.64 M | ||
|
CohBar
CWBR
|
349 K | - | -15.44 % | $ 2.2 M | ||
|
NeuBase Therapeutics
NBSE
|
110 K | - | -1.56 % | $ 12.3 M | ||
|
Epizyme
EPZM
|
216 M | - | - | $ 249 M | ||
|
Arena Pharmaceuticals
ARNA
|
8.3 M | - | -6.81 % | $ 3.04 B | ||
|
Nabriva Therapeutics plc
NBRV
|
388 K | - | - | $ 4.55 M | ||
|
scPharmaceuticals
SCPH
|
51.4 M | - | - | $ 218 M | ||
|
Entasis Therapeutics Holdings
ETTX
|
704 K | - | - | $ 105 M | ||
|
Athersys
ATHX
|
7.94 M | - | 3.77 % | $ 22.4 M | ||
|
Global Blood Therapeutics
GBT
|
246 M | - | - | $ 4.62 B | ||
|
Inozyme Pharma
INZY
|
31.5 M | - | - | $ 207 M | ||
|
NanoString Technologies
NSTG
|
227 M | - | -37.43 % | $ 5.1 M | ||
|
Humanigen
HGEN
|
25 M | - | -81.12 % | $ 4.28 M | ||
|
Sorrento Therapeutics
SRNE
|
19.1 M | - | -29.58 % | $ 126 M | ||
|
Surface Oncology
SURF
|
24.7 M | - | - | $ 59.7 M | ||
|
Sierra Oncology
SRRA
|
485 K | - | -0.05 % | $ 1.34 B | ||
|
Vaccinex
VCNX
|
26 K | - | -61.37 % | $ 654 K | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
931 K | - | -19.68 % | $ 18.4 M | ||
|
Jounce Therapeutics
JNCE
|
5.87 M | - | - | $ 98.4 M | ||
|
Cocrystal Pharma
COCP
|
1.17 M | $ 0.93 | -4.11 % | $ 10.5 M |